Aarhus, Sept 1, 2006 ReceptIcon today announced the appointment of Dr. Hans T. Schambye as Chief Executive Officer. This marks the first step in the transformation of ReceptIcon to a full fledged R&D biotech company following its successful financing earlier this year.
“We are excited to have Hans join us as our new CEO” says Steen Helde Hemmingsen, Chairman of ReceptIcon’s Board of Directors. “Hans brings a lot of knowledge and experience to ReceptIcon. The Company has reached a number of important milestones in the past year and is now at an important inflection point. I look forward to working with Hans and overseeing the next important developments.”
Dr. Schambye previously served as Chief Executive Officer of Gastrotech Pharma A/S, a Danish clinical stage biotech company. Before joining Gastrotech, Dr. Schambye was Director of Biology and Pharmacology and Head of Portfolio Management at Maxygen, a US biotech company. In 1999, Dr. Schambye co-founded ProFound Pharma A/S, a Danish biotech company, which was acquired by Maxygen in 2000. Previously, Dr. Schambye was a project manager at Novo Nordisk. Prior to this Dr. Schambye had a successful research career at Stanford University and Copenhagen University within the field of receptor biology. Dr. Schambye holds an MD from Odense University and a PhD in Medical Sciences from Copenhagen University.
“I look very much forward to joining ReceptIcon” says Dr. Schambye. “The company is based on exceptional science and the founders, Anders Nykjær and Thomas Willnow, have managed to make remarkable progress in very little time. The company has identified several lead compounds with very promising attributes and I am excited to be part of bringing these towards clinical testing and ultimately the market”
About ReceptIcon ApS: ReceptIcon is a spin-out from a research collaboration between the University of Aarhus and the Max Delbrück Center for Molecular Medicine in Berlin. The company is based on research that led to the identification of a protein, Megalin, which mediates the kidney damage caused by many important and frequently used drugs. ReceptIcon has developed a number of compounds capable of blocking Megalin and thus preventing kidney damage. ReceptIcon intends to develop these compounds for the treatment of various important unmet medical needs, including prevention of kidney failure. The Company’s investors include InnovationsKapital, INCUBA Venture, Dansk Erhvervsinvestering, VECATA A/S, and Oestjysk Innovation.
For further information, please contact:
Dr. Hans Schambye, CEO, ReceptIcon, at +45 8620 5190
